Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trialAchim Rittmeyer, David R. Gandara, Fabrice Barlési et al.|The Lancet|2016Cited by 4.8k
Analysis of <i>Epidermal Growth Factor Receptor</i> Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to GefitinibTakayuki Kosaka, Tetsuya Mitsudomi, Yasushi Yatabe et al.|Clinical Cancer Research|2006Cited by 589
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alterationAlexander Drilon, Paul K. Paik, Liza C. Villaruz et al.|Nature Medicine|2020Cited by 393
Combined Survival Analysis of Prospective Clinical Trials of Gefitinib for Non–Small Cell Lung Cancer with <i>EGFR</i> MutationsSatoshi Morita, Toshihiro Nukiwa, Isamu Okamoto et al.|Clinical Cancer Research|2009Cited by 189
Meta-analysis of genome-wide association studies identifies multiple lung cancer susceptibility loci in never-smoking Asian womenZhaoming Wang, Wu‐Chou Su, Wei Jie Seow et al.|Human Molecular Genetics|2016Cited by 58